June 4, 2013 by Arezu Sarvestani Mass Device
During the last month the medtech titans were flush with news from conferences, court rooms and Wall Street.
Minnesota giant Medtronic (NYSE:MDT) hit new highs after issuing its Q4 2013 earnings report, unveiled updates from trials of its renal denervation and TAVI devices and sparred with rivals over patents and batteries.
Johnson & Johnson (NYSE:JNJ) jumped into a prominent seat on the list with stories driven largely by the ongoing metal-on-metal hip lawsuits (and a failure to appeal a $8.3M verdict) as well as by some legal battles over copyrights and spine patents.
Covidien (NYSE:COV) slid to 3rd place in May with stolen merchandise and new financials ahead of a pharma spinout. Boston Scientific (NYSE:BSX) remained 4th with a dramatic overseas legal battle with OrbusNeich (which asked police to seize BoSci's stents) and a patent tussle with Medtronic that's headed for the Supreme Court.
Johnson & Johnson
- Bellwether federal trial against DePuy delayed
- J&J's Ethicon Endo-Surgery wins FDA approval for Sedasys computer-assisted anesthesia device
- Another recall for Johnson & Johnson Down Under
- Globus Medical sues J&J's DePuy Synthes unit over spine implant patent
- Johnson & Johnson's DePuy will stop selling metal-on-metal implants
- Can Johnson & Johnson fire on all cylinders again?
- Judge orders J&J's DePuy Orthopaedics to produce compliance reports
- Biosense Webster launches Afib ablation study for nMARQ system
- J&J sues Shasta Technologies for logo infringement
- Johnson and Johnson executive splits for the corner office at Itamar Medical
- J&J's DePuy can't dodge $8.3M metal hip implant verdict
- News Well, Trends